Global Debut of a New Paradigm: Ausmed Medical Device OPC Innovation Community Unveiled at Guangzhou Finance Expo

A surgeon identifies clinical pain points in the operating room, while a scientist achieves technological breakthroughs in the laboratory. Although they possess innovative ideas with high translational value, they often encounter significant barriers during the process of translating these innovations into practical applications—regulatory interpretation, registration and filing, establishment of production systems, and fundraising can each present formidable obstacles.

In China, the conversion rate of scientific and technological achievements in medical devices has long remained below 5%. Zhang Feng, Chairman of Osida Group, pointed out in an interview with VCBeat: “The market value of a single medical device patent is typically less than RMB 100,000, and the failure rate of commercialization has long stayed at a high level of over 90%.”

On June 5, at the 15th China (Guangzhou) International Financial Transaction & Expo, Osida will officially launch the Medical Device OPC Innovation Community to a global audience and hold the kickoff ceremony for strategic industrial ecosystem partnerships. Centered on the core concept of the “One Person Company” (OPC), this innovative platform aims to address critical bottlenecks in China’s medical device technology transfer chain and bridge the gap between scientific research achievements and commercialization through its integrated “Cloud Factory” model.

Innovation in medical devices primarily stems from two sources: one is clinical innovation, referring to the clinical pain points identified by frontline physicians during surgeries and diagnoses; the other is technological innovation, involving new materials and technologies developed by universities and research institutes. However, regardless of the source, both face the same dilemma—a hindered translation pathway.

Zhang Feng summarized the multiple challenges in translating medical device research into commercial products: developers must navigate hundreds of regulatory requirements, complete registration filings, establish quality management systems, and secure funding for R&D and production, while also managing teams, building manufacturing facilities, and procuring specialized equipment. “A clinical expert transitioning from their specialized field to become a corporate manager must handle extensive daily administrative tasks unrelated to R&D,” said Zhang Feng. “The success rate of such translation efforts has long remained low.”

With 22 years of deep expertise in the medical device CRO/CDMO sector, Ozda has served over 5,000 clients and facilitated the acquisition of more than 3,600 global regulatory approvals (covering major markets including China, the United States, and the European Union). It is this accumulation of experience over two decades that has led Zhang Feng to recognize that the bottlenecks in translating scientific and technological achievements are not isolated issues, but systemic ones.

“Previously, each segment of the industry chain was relatively fragmented, with stakeholders participating only in the areas where they had the greatest expertise or profitability,” said Zhang Feng. “However, when multiple segments are integrated sequentially, the overall success rate declines significantly.”

This also represents the core value of the OPC Innovation Community, a closed-loop platform covering the entire chain of “evaluation–patenting–financing–R&D–registration–production–sales.” Zhang Feng summarizes it as a tripartite “Cloud-Factory” architecture: the “Edge” (OZD Medical Device Innovation Intelligent Agent Terminal) serves as the individual access point; the “Cloud” (AI Medical Device Cloud Platform) comprises vertical-domain large language models and specialized knowledge bases; and the “Factory” (OLABS Innovation Factory) is the physical production base.

“From devices to the cloud, empowered by the cloud, and implemented in factories,” said Zhang Feng. “We aim to eliminate all bottlenecks in the chain of translating medical device innovations into practical applications.”

The core of OPC is the “one-person company” concept. A physician or scientist with an innovative idea can receive end-to-end support within the OPC community, covering the entire journey from concept to market launch, and even engage in lifelong learning within the OPC community.

Zhang Feng shared several case studies that had previously been implemented in practice.

The first case involves a physician from The University of Hong Kong-Shenzhen Hospital. He had an innovative clinical idea but wished to remain in his clinical role. Ozda assisted him with patent evaluation, commercialization analysis, prototype development, and regulatory submission. The project is now valued at RMB 70 million, while the physician continues to work on the clinical frontline. “Let professionals handle professional tasks,” said Zhang Feng. “A physician’s core value lies in clinical practice, while the translation of innovations into marketable solutions should be supported by specialized platforms.”

The second case involves a Suzhou-based enterprise. This company completed its R&D validation from 0 to 1 in the laboratory, and after joining MedSci’s Shanghai Innovation Factory, it advanced industrialization from 1 to 10. The company’s valuation grew from RMB 50–60 million to RMB 900 million, and it successfully achieved an exit through merger and acquisition a year and a half later. “Without the support of a professional platform, this process would typically take more than six years,” said Zhang Feng.

The third case involves Nikkiso Co., Ltd., a publicly listed company in Japan. Its products have already been launched in the Japanese market but require completion of local registration in China. If pursued independently, this process was estimated to take two to three years. With assistance from Ozda, the integration of the local supply chain and the submission of registration applications were completed in just over one year.

These three cases respectively represent three types of innovation entities: physician/scientist entrepreneurs starting from scratch, innovative enterprises scaling from 1 to 10, and large multinational corporations entering the Chinese market from overseas. Zhang Feng stated, “The OPC Innovation Community is not a concept devised out of thin air, but a systematic platform developed based on a decade of practical experience.”

The launch of the OPC Innovation Community coincides with a period of rapid advancement in artificial intelligence technology. However, for Osida, it represents a natural culmination of long-term accumulation.

Zhang Feng revealed that Ozda began advancing its digital transformation around 2016. At the time, the company was simultaneously serving over a thousand projects annually, a scale that was difficult to sustain through manual management alone. “We independently developed an internal management system and continuously built our own databases and knowledge bases.” By 2024, when Ozda partnered with Huawei to co-establish the “China Medical Device Industry Cloud,” its cumulative investment in digitalization had reached tens of millions of yuan.

“Tasks that previously required significant manpower are now more efficient with the aid of AI technology,” said Zhang Feng.

Aozhida’s AI capabilities are powered by a vertical-domain model trained on 22 years of industry-specific data. Zhang Feng provided an example: “When we input report content into general-purpose large language models for testing, the output differed significantly from actual requirements. Our vertical model is built upon service data from 5,000 clients and experience with over 3,600 regulatory registration submissions—capabilities that general models lack.” Currently, Aozhida’s AI tools can support functions such as automated generation of patent evaluation reports and automated analysis of commercial feasibility. A professional report spanning hundreds of pages, which previously required a specialized team several weeks to complete, can now be generated in near real-time.

“Our goal is not to ‘embrace AI,’ but to ‘become an AI-driven platform,” said Zhang Feng. “The current development direction of Ozeda is driven by the dual engines of ‘industrial AI + industrial translation.’”

Notably, the underlying logic of the OPC Innovation Community aligns closely with the development direction of “AI + Lightweight Technological Innovation” outlined in the 15th Five-Year Plan. Against the strategic backdrop of the state’s vigorous promotion of scientific and technological achievement transformation and support for innovation-driven development in the medical device sector, Ozeda has provided a replicable and scalable practical model for building the medical device industry ecosystem through its integrated “Cloud Factory” tripartite model.

On June 5, during the 15th Guangzhou International Financial Fair, the Global Launch of the Medical Device OPC Innovation Community and the Kickoff Ceremony for the Ozda Industrial Ecosystem Strategic Partnership will officially commence. Guided by the People’s Government of Yuexiu District, Guangzhou, and hosted by Ozda with VCBeat as the organizer, the event will bring together representatives from national ministries, municipal leaders, authoritative industry experts, and stakeholders from academia, research, industry, and investment sectors.

The press conference features a diverse array of highlights: from keynote speeches, the unveiling of the Innovation Center, and strategic cooperation signings, to the onboarding of high-quality innovation and entrepreneurship projects, comprehensively showcasing a new landscape of the innovative ecosystem in the medical device industry. Mr. Zhang Feng, Chairman of Osmunda, will unveil the core components of the Medical Device OPC Innovation Community on-site and provide an in-depth interpretation of the development plan for building a global medical device innovation ecosystem platform. Distinguished guests, including economics experts, representatives from the Service Trade Professional Committee, and the Shanghai Institute for Clinical Translation, will share cutting-edge insights and jointly explore new pathways for the high-quality development of the industry.

In addition, a signing ceremony will be held on-site for the entry of innovative medical device startups into the OPC Community. Leaders from the Bureau of Industry and Information Technology and the Bureau of Science and Technology will deliver remarks, while representatives of outstanding projects will share their experiences, showcasing the first batch of settled projects.

For the local area, the establishment of the OPC Innovation Community signifies a “convergence of talent, technology, and industry.”

In the interview, Zhang Feng pointed out that many provincial capital cities possess top-tier Grade 3A hospital resources, yet suffer from significant outflow of innovative achievements due to the lack of professional platforms for outcome translation. Through its “Cloud Factory” model, the OPC Community keeps doctors’ clinical innovations and scientists’ technological patents within the locality for translation, thereby realizing the goal of “keeping patents, tax revenue, and talent here.” Meanwhile, the community’s supporting industrial funds and financial innovation collaborations will further leverage social capital toward early-stage medical device projects, providing sustainable industrial ecosystem support for establishing the region as a highland of medical device innovation.

Aozhida’s ambitions extend beyond China. According to reports, the global expansion of the OPC Innovation Community is already in the planning stages, with Europe and North America prioritized as the initial targets for internationalization. “Overseas markets also need such a platform,” stated Zhang Feng. “China’s manufacturing capabilities and supply chain systems offer competitive advantages on a global scale, and we aim to replicate this model in broader international markets.”

Ouzida will officially unveil the OPC Innovation Community. For doctors and scientists who possess innovative ideas but are constrained by commercialization pathways, this “one-person company” innovation platform may well be the long-awaited solution they have been seeking.

Click below to register and sign up

Global Launch of the Medical Device OPC Innovation Community

Launch Ceremony of the Strategic Partnership in the Industrial Ecosystem with Aozida

https://vb100.mike-x.com/AdSNj